|
- Precision oncology with selective RET inhibitor selpercatinib in
Activating RET alterations can occur and lead to uncontrolled cellular proliferation as a hallmark of cancer development Oncogenic RET fusions are present in nearly 2% of patients with non-small cell lung cancer (NSCLC), 10–20% of patients with thyroid cancer, and <1% across the pan-cancer spectrum
- First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET . . .
Selpercatinib, a highly selective potent and brain-penetrant RET inhibitor, was shown to have efficacy in patients with advanced RET fusion–positive non–small-cell lung cancer (NSCLC) in
- FDA approves selpercatinib for locally advanced or metastatic RET . . .
On September 21, 2022, the Food and Drug Administration granted accelerated approval to selpercatinib (Retevmo, Eli Lilly and Company) for adult patients with locally advanced or metastatic
- Rapid response to selpercatinib in RET fusion positive pancreatic . . .
This case report describes the efficacy of selpercatinib, a selective RET inhibitor, in an unusual case of large-cell neuroendocrine pancreatic carcinoma (LCNEPAC) harboring a CCDC6::RET
- Exceptional Responses to Selpercatinib in RET Fusion–Driven Metastatic . . .
Efficacy and Tolerability of Osimertinib and Sotorasib Combination Treatment for Osimertinib Resistance Caused by KRAS G12C Mutation: A Report of Two Cases Lasofoxifene Monotherapy Induces Durable Complete Remission in a Patient with Estrogen Receptor-Positive, Metastatic Breast Cancer with an ESR1 Mutation
- First-line selpercatinib for a patient with RET fusion-positive . . .
In this case report, we describe the successful use of selpercatinib, RET (rearranged during transfection) kinase inhibitor, as a first-line treatment in a patient with advanced pulmonary LCNEC harboring a RET fusion gene
- FDA Approval Summary: Selpercatinib for the treatment of advanced RET . . .
On May 8, 2020, FDA granted accelerated approval to selpercatinib for the treatment of adult patients with metastatic RET fusion-positive NSCLC, the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET -mutant medullary thyroid cancer (MTC) who require systemic therapy, and the treatment of adult
- Precision oncology with selective RET inhibitor selpercatinib in RET . . .
In this article, we review the current status on the use of the selective RET inhibitor, selpercatinib, in RET fusion-positive tumors: NSCLC, thyroid cancers, and the more recent tissue-agnostic activity leading to FDA approval The rearranged during transfection (RET) gene is a protooncogene that is located on chromosome 10
|
|
|